Market leader in 3D cell culture
InSphero AG
Incorprated
26.03.2009Headquarters
SchlierenSupport
InSphero is a global leader in scalable, reliable, and reproducible 3D cell culture technology and solutions for drug safety and efficacy testing. Based in Switzerland, the European hub for advancing non-animal drug testing methods, the company has been a trusted partner to major pharmaceutical organizations, academic institutions and regulators since 2009, supporting their efforts to develop safer and faster drug development solutions.
The company’s mission to unlock the full potential of 3D in vitro models is realized through its comprehensive ecosystem of industry-grade technologies and the deep expertise of its scientific and operational teams. Together, they empower researchers to generate biologically and physiologically relevant data, enabling innovation in drug discovery.
Awards
News
Biotech startups celebrate new achievements (startupticker.ch)
InSphero secures an EU grant to advance diversity in 3D in vitro testing (venturelab.swiss)
Bio Europe in Stockholm hosts 33 Swiss companies (startupticker.ch)
From Glial Cells to Beta Cells: Swiss companies receive grants to tackle health challenges (startupticker.ch)
Swiss life science startups headed for San Diego (startupticker.ch)
InSphero obtains strategic investment from ZEISS Ventures (venturelab.swiss)
ZEISS Ventures invests in InSphero to drive 3D cell culture research (startupticker.ch)
InSphero and Brenus Pharma are awarded EUR 1.5 million grant for cancer research project (venturelab.swiss)
New prizes and grants from three continents (startupticker.ch)
Insphero among Red Dot’s Best of the Best Award winners (startupticker.ch)
Swiss Startups Tackling Corona Virus - COVID-19 (venturelab.swiss)
Tried and tested technologies to fight Coronavirus (startupticker.ch)
Jan Lichtenberg, CEO of InSphero, About Measures Taken During The Coronavirus Crisis (venturelab.swiss)
IPO Day: Deep-tech companies on stage (startupticker.ch)
Twelve Swiss startups join Euronext?s Pre-Ipo programme Techshare (startupticker.ch)
Insphero?s 3D liver disease testing platform launched in the market (startupticker.ch)
Applications are open for Venture Leaders China Roadshow 2019 (venturelab.swiss)
Applications are now open for Venture Leaders Life Sciences roadshow 2019 (venturelab.swiss)
Insphero collaborates with the American Laboratory Products Company (startupticker.ch)
InSphero raises additional $10m (startupticker.ch)
Milestones news
InSphero Partners with Chayon to Bring Advanced 3D In Vitro Technologies to South Korean Researchers
InSphero and PharmaNest Unveil a Promising Tool for MASH Drug Discovery in a Breakthrough Study
InSphero Strengthens its Executive Team by Appointing Paul Clémençon, MBA as Chief Business Officer
Physicians Committee for Responsible Medicine and InSphero?Announce the Winners of the HUMAIN Award
InSphero to Revolutionize Oncology Research Through Advanced 3D Cell-Based Assays with ATCC
InSphero Enables Novel Drug Discovery in Liver Disease by Launching the MASH CALL Initiative
InSphero and Yokogawa Enter into Partnership Agreement to Support Drug Development Research
InSphero hosts first New Frontiers in 3D Cell Culture-based Screening Technologies Conference
InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury
InSphero partners with Roche and others to further develop its 3D microtissue technology in a European grant project HeCaTos
InSphero triples its turnover in 2011
Global top-10 cosmetics company closes exclusive supply deal with InSphero
Videos and Presentations
120 sec introduction to cancer applications of InSphero's 3D InSight™ Tumor Microtissues
90 sec introduction to InSphero's 3D InSight™ Liver Microtissues
InSphero at IFJ
InSphero company video